 Breda, the Netherlands Ghent, Belgium argenx Euronext Nasdaq: ARGX, a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, announced today that it has commenced a global offering of 500 million approximately 458.3 million of ordinary shares, which may be represented by American Depository Shares ADSs. The global offering will be comprised of an offering of ordinary shares represented by ADSs in the United States and certain other countries outside of the European Economic Area and a simultaneous private placement of ordinary shares in the European Economic Area. 